

Joseph A Dimasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4039270/publications.pdf>

Version: 2024-02-01

48
papers

9,890
citations

218381

26
h-index

197535

49
g-index

52
all docs

52
docs citations

52
times ranked

8096
citing authors

#	ARTICLE	IF	CITATIONS
1	The price of innovation: new estimates of drug development costs. <i>Journal of Health Economics</i> , 2003, 22, 151-185.	1.3	3,576
2	Innovation in the pharmaceutical industry: New estimates of R&D costs. <i>Journal of Health Economics</i> , 2016, 47, 20-33.	1.3	2,229
3	Cost of innovation in the pharmaceutical industry. <i>Journal of Health Economics</i> , 1991, 10, 107-142.	1.3	622
4	The cost of biopharmaceutical R&D: is biotech different?. <i>Managerial and Decision Economics</i> , 2007, 28, 469-479.	1.3	449
5	Risks in new drug development: Approval success rates for investigational drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 297-307.	2.3	375
6	Economics of New Oncology Drug Development. <i>Journal of Clinical Oncology</i> , 2007, 25, 209-216.	0.8	317
7	Returns on Research and Development for 1990s New Drug Introductions. <i>Pharmacoeconomics</i> , 2002, 20, 11-29.	1.7	230
8	New drug development in the United States from 1963 to 1999. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 286-296.	2.3	218
9	The Value of Improving the Productivity of the Drug Development Process. <i>Pharmacoeconomics</i> , 2002, 20, 1-10.	1.7	201
10	Success rates for new drugs entering clinical testing in the United States. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 1-14.	2.3	169
11	Research and Development Costs for New Drugs by Therapeutic Category. <i>Pharmacoeconomics</i> , 1995, 7, 152-169.	1.7	159
12	The Economics of Follow-on Drug Research and Development. <i>Pharmacoeconomics</i> , 2004, 22, 1-14.	1.7	156
13	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 220-229.	0.8	96
14	Competitiveness in follow-on drug R&D: a race or imitation?. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 23-27.	21.5	90
15	The Cost of Drug Development. <i>New England Journal of Medicine</i> , 2015, 372, 1972-1972.	13.9	90
16	R&D Costs and Returns by Therapeutic Category. <i>Drug Information Journal</i> , 2004, 38, 211-223.	0.5	85
17	Drug development costs when financial risk is measured using the Fama-French three-factor model. <i>Health Economics (United Kingdom)</i> , 2009, 19, 1002-1005.	0.8	82
18	New drug development in the United States from 1963 to 1992. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 609-622.	2.3	65

#	ARTICLE	IF	CITATIONS
19	Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process. <i>Pharmacoeconomics</i> , 2001, 19, 753-766.	1.7	52
20	R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry. <i>International Journal of the Economics of Business</i> , 1995, 2, 201-219.	1.0	51
21	New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms. <i>Drug Information Journal</i> , 2000, 34, 1169-1194.	0.5	51
22	The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation. <i>Health Affairs</i> , 2015, 34, 302-310.	2.5	50
23	New drug development in the United States from 1963 to 1990. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 471-486.	2.3	42
24	Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 759-768.	0.8	37
25	Measuring the Pace of New Drug Development in the User Fee ERA. <i>Drug Information Journal</i> , 2000, 34, 673-680.	0.5	36
26	Extraordinary claims require extraordinary evidence. <i>Journal of Health Economics</i> , 2005, 24, 1034-1044.	1.3	29
27	Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications. <i>Clinical Therapeutics</i> , 2013, 35, 808-818.	1.1	29
28	Private Sector Contributions to Pharmaceutical Science: Thirty-Five Summary Case Histories. <i>American Journal of Therapeutics</i> , 2010, 17, 101-120.	0.5	26
29	Pharmaceutical R&D Performance by Firm Size. <i>American Journal of Therapeutics</i> , 2014, 21, 26-34.	0.5	26
30	Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 324-332.	2.3	26
31	Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. <i>Clinical Therapeutics</i> , 2017, 39, 1409-1425.e20.	1.1	23
32	Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 608-618.	2.3	22
33	R&D Costs and Returns to New Drug Development: A Review of the Evidence. , 0, , 21-46.		22
34	Setting the record straight on setting the record straight: Response to the Light and Warburton rejoinder. <i>Journal of Health Economics</i> , 2005, 24, 1049-1053.	1.3	19
35	Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences. <i>Drug Information Journal</i> , 1997, 31, 771-788.	0.5	18
36	Assessing Pharmaceutical Research and Development Costs. <i>JAMA Internal Medicine</i> , 2018, 178, 587.	2.6	15

#	ARTICLE	IF	CITATIONS
37	The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. <i>Therapeutic Innovation and Regulatory Science</i> , 2014, 48, 482-487.	0.8	14
38	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 72-80.	2.9	13
39	Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing. <i>Clinical Therapeutics</i> , 2018, 40, 963-972.	1.1	8
40	New Indications for Already-Approved Drugs: An Analysis of Regulatory Review Times. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 205-215.	1.0	6
41	An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989-1994. <i>Drug Information Journal</i> , 1996, 30, 315-337.	0.5	6
42	Research and Development Costs of New Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 517.	3.8	6
43	Strategic, feasibility, economic, and cultural aspects of phase 0 approaches. <i>Clinical and Translational Science</i> , 2022, 15, 1355-1379.	1.5	6
44	The Financial Benefits of Faster Development Times: Integrated Formulation Development, Real-Time Manufacturing, and Clinical Testing. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1453-1460.	0.8	5
45	The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development ??? The Authors?? Reply. <i>Pharmacoeconomics</i> , 2005, 23, 1193-1202.	1.7	4
46	Mandatory Comparator Trials for Therapeutically Similar Drugs: An Assessment of the Facts. <i>American Journal of Therapeutics</i> , 2007, 14, 231-234.	0.5	2
47	Analysis of Review Times for Recent 505(b)(2) Applications. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 651-656.	0.8	2
48	Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation. , 2017, , 63-73.		0